enGene achieves target enrollment in LEGEND trial of detalimogene voraplasmid

enGene (ENGN) announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid in patients with high-risk, non-muscle invasive bladder cancer. LEGEND’s pivotal Cohort 1 is studying detalimogene in patients with high-risk NMIBC with carcinoma in-situ with or without concomitant papillary disease. Patients in the screening process remain eligible for potential enrollment in the trial. The company expects to overenroll in its pivotal cohort resulting in an adjustment in guidance for a BLA submission to 2H 2026.